Onco-Nephrology Symposium

  • Continuing Education
A health care provider pointing to a demonstration of a kidney.

-

Registration Deadline: September 18, 2026

Advance your onco-nephrology expertise by joining a dynamic, expert-led symposium designed to equip clinicians with up-to-date knowledge at the intersection of cancer and kidney care. Gain practical insights, emerging evidence, and multidisciplinary strategies to better diagnose, manage, and support the growing population of cancer patients facing complex renal conditions.

  • Live Online or In Person

This course is taught in person and live online.

Dana Farber Cancer Institute | 450 Brookline Avenue, Boston, MA 02215

This is the standard price, for a full list of profession pricing see below.
View All

Continuing Education

Earn up to:
15.00 AMA PRA Category 1 Credit(s) ™
View All

Two Days

Please view the Schedule for a full description of the program.

On This Page

Overview

At least 1 out of every 10 cancer patients will experience acute kidney injury, and up to 25% will have chronic kidney disease. Cancer is a common global problem, and as cancer treatments evolve, nephrologists will be tasked with diagnosing and managing more complex cases within this cohort of patients. The 2026 Onco-Nephrology Symposium will offer up to date information and insights from national and international experts in this constantly evolving subspecialty. The goal of this forum is to provide an opportunity for academicians and clinicians to have personal exchanges with experts in this steadily expanding subspecialty in order to enhance the clinical experience of our cancer patients. Topics covered will include an update on cancer therapies and renal impact, paraneoplastic glomerular disorders, thrombotic microangiopathy, and monoclonal disorders, to name a few. This symposium is intended for physicians, advanced practice providers, nurses, medical students, and other health care professionals in Hospital Medicine, Internal Medicine, Nephrology, Hematology, and Oncology. 

Learning Objectives

  • Diagnose and manage various forms of renal complications in patients with cancer.
  • Understand the landscape of cancer therapy including chemo, cellular, immune, and targeted therapy with update on reno-protective strategies.
  • Review cancer associated with glomerular disease, thrombotic microangiopathy, and monoclonal gammopathies with updates on latest diagnostics and management.
  • Consider the role of kidney transplant in patients with cancer.
  • Learn to work in a multi-disciplinary group of providers to enhance the experience of our patients with cancer.

Developed and Offered By:

  • Brigham and Women's Hospital logo
  • Dana-Farber Cancer Institute Logo

Continuing Education courses are developed by faculty from Harvard Medical School's teaching hospitals and accredited by Harvard Medical School. This course is offered by Brigham and Women's Hospital and Dana Farber Cancer Institute.

Who Should Participate

MDs and DOs

Faculty

Harvard Medical School Continuing Education attracts the best and brightest faculty from all around the world. As a student in this course, you’ll have access to outstanding course directors and faculty.

 

Course Directors

Ala Abudayyeh, MD
Associate Professor and Director of Clinical Research, MD Anderson Cancer Center

Allison Betof, MD, PhD
Director, Solid Tumor Cellular Therapy;
Associate Professor, Stanford University School of Medicine

Christopher Blosser, MD
Director, Center for Innovations in Cancer & Transplant (CICT), and Cancer & Organ Transplant Clinic (COTC);
Professor of Medicine, University of Washington

Jorge J. Castillo, MD
Clinical Director, Bing Center for Waldenström Macroglobulinemia, Dana Farber Cancer Institute;
Associate Professor, Harvard Medical School

Api Chewcharat, MD
Instructor in Medicine, Brigham and Women's Hospital, Harvard Medical School

Corey Cutler, MD, MPH
Past President, American Society for Transplantation and Cellular Therapy;
Director, Adult Stem Cell Transplantation Program, Dana Farber Cancer Institute

Samantha Gelfand, MD

Sandra M. Herrmann, MD
Professor of Medicine, Mayo Clinic

Abdullah Jalal, MD
Brigham and Women's Hospital;
Instructor in Medicine, Harvard Medical School

Anuja Java, MD
Associate Professor, Washington University

Kenar Jhaveri, MD
Professor of Medicine, Associate Chief in the Division of Kidney Diseases and Hypertension, Northwell Health and Zucker School of Medicine

Abhijat Kitchlu, MD, MSc, FRCPC
Director, University Health Network Onco-Nephrology Program; 
Assistant Professor, University of Toronto

David E. Leaf, MD
Associate Professor, Brigham and Women's Hospital, Harvard Medical School

Nelson Leung, MD
Professor of Medicine, David L. and Colleen B. Kessenich Professor in Multiple Myeloma, Mayo Clinic

Nikhil C. Munshi, MD
Immediate Past President, International Myeloma Society;
Director, Basic and Correlative Science Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute;
Professor of Medicine, Harvard Medical School

Sarah Nikiforow, MD, PhD
Technical Director, Immune Effector Cell Therapy Program;
Medical Director, Connell and O'Reilly Families Cell Manipulation Core Facility, Dana Farber Cancer Institute;
Assistant Professor of Medicine, Harvard Medical School

Vaishali Sanchorawala, MD
Director, Amyloidosis Center; 
Director, Stem Cell Transplant, Boston Medical Center;
Professor, Boston University

Harish Seethapathy
Assistant Professor, Massachusetts General Hospital, Harvard Medical School

Aisha Shaikh, MD, PhD
Director, Onconephrology, University of Pennsylvania

Elad Sharon, MD, MPH
Clinical and Translational Director of the Immunotherapy Toxicity Program, Dana-Farber Cancer Institute;
Associate Professor of Medicine, Harvard Medical School

Christophe Sirac, PhD
Professor of Immunology, University of Limoges

Meghan Sise, MD
Director, Onconephrology, Massachusetts General Hospital (MGH);
Associate Professor of Medicine, Harvard Medical School.

María José Soler, MD, PhD
Chief, Clinical Nephrology and Dialysis Unit, Hospital Universitari Vall d'Hebron

Sumithra Vasu, MD
Professor of Medicine, Ohio State University

Astrid Weins, MD, PhD
Chief, Renal Pathology, Mass General Brigham;
Assistant Professor, Harvard Medical School

Biruh T. Workeneh, MD, FASN
Associate Professor, MD Anderson Cancer Center 

Complete Your Registration

Started a registration? Log in to enroll today.

Request Information

Interested in learning more about this program? Sign up for details.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Course Fees

Fee Disclaimer

You may register through our secure online environment and will receive an email confirmation upon receipt of your payment. Prices include CME credit, electronic syllabus. At the end of the registration process, a $10 non-refundable processing fee will be added to your registration.

Review the cancellation policy.

Role Course Fee

Accreditation

In support of improving patient care, Harvard Medical School is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Harvard Medical School designates this live activity for a maximum of 15.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For the purpose of recertification, the American Academy of Nurse Practitioners Certification Board and American Nurses Credentialing Center accept AMA PRA Category 1 Credit™ issued by organizations accredited by the ACCME (Accreditation Council for Continuing Medical Education). We would also suggest that learners check with their state licensing board to ensure they accept reciprocity with AMA PRA Category 1 Credit™ for re-licensure.

Harvard Medical School has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 7.50 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

The American Medical Association (AMA) has an agreement of mutual recognition of continuing medical education (CME) credit with the European Union of Medical Specialties (UEMS). Additional information regarding this agreement may be found on the European Union of Medical Specialties website.

The Royal College of Physicians and Surgeons of Canada recognizes conferences and workshops held outside of Canada that are developed by a university, academy, hospital, specialty society or college as accredited group learning activities.

Registration for courses managed by Harvard Medical School can only be completed through Harvard Medical School’s official registration portal: cmeregistration.hms.harvard.edu. Attendee registrations made through any other sites cannot be honored and will not be refunded. Please report any unauthorized websites or solicitations for registrations.

Program Topics